• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics

Senseonics reports mixed Q3 results, positive Eversense 365 outlook

November 8, 2024 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) shares dipped slightly before hours today on third-quarter results that came in mixed compared to the consensus forecast. Shares of SENS fell 2.5% to 34¢ apiece in pre-market trading today. The Germantown, Maryland-based implantable continuous glucose monitor (CGM) maker reported losses of $23.98 million. That equals 4¢ per share on sales of $4.26 […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Senseonics

Senseonics announces $16M registered direct offering

October 25, 2024 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) announced today that it entered into a definitive agreement to offer $16 million in common stock. Germantown, Maryland-based Senseonics plans to offer more than 45.7 million shares of common stock. It priced the shares at 35¢ per share in a registered direct offering. In a concurrent private placement, the company agreed to issue […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.

October 1, 2024 By Sean Whooley

Senseonics Ascensia Eversense 365 Product image

Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S. Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes aged 18 years and older. Senseonics announced last month that it received FDA clearance for Eversense 365. With […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Ascensia Diabetes Care, Senseonics

Senseonics wins FDA nod for 365-day implantable CGM

September 17, 2024 By Sean Whooley

Senseonics Eversense 365 Product Image

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: Ascensia Diabetes Care, FDA, Senseonics

The 9 largest diabetes technology companies in the world

August 21, 2024 By Sean Whooley

9 largest diabetes companies in the world abbott dexcom medtronic insulet

Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott, Dexcom, embecta, Insulet, Medtronic, Roche Diabetes Care, Senseonics, Tandem Diabetes Care, Ypsomed

Senseonics misses Q2 sales expectations but 365-day CGM is on track for Q4 launch

August 8, 2024 By Sean Whooley

Ascensia Senseonics Eversense E3 implantable long-term CGM

Senseonics (NYSE:SENS) shares dipped after hours today on second-quarter results that missed the consensus sales forecast. Shares of SENS  fell 4% to 39¢ apiece in post-market trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up nearly 1%. The Germantown, Maryland-based long-term implantable […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Senseonics

The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions

June 25, 2024 By Sean Whooley

ADA 2024 Product Images Dexcom Abbott Senseonics Ascensia Insulet Tandem Medtronic Sequel

The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Patient Monitoring, Pharmaceuticals, Technology Tagged With: abbott, Dexcom, embecta, Insulet, mannkind, Medtronic, Senseonics, Sequel Med Tech, Tandem Diabetes Care

The steps ahead for the Eversense implantable CGM platform

June 24, 2024 By Sean Whooley

Ascensia Senseonics Eversense E3 implantable long-term CGM

As Senseonics and Ascensia Diabetes Care looked for someone to help scale their CGM business, they turned to someone had only just retired. After close to eight years as Tandem Diabetes Care CCO, Brian Hansen notified the company of his decision to step down last August. His final day landed on Dec. 31, but he […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2024, Ascensia Diabetes Care, Senseonics

Senseonics expects a Q4 launch for 365-day CGM, offers full-year outlook

June 21, 2024 By Sean Whooley

Marketing image Senseonics Eversense E3 Ascensia Diabetes Care

Senseonics (NYSE:SENS) today shared its full-year financial outlook and laid out expectations for a new product launch this year. The Germantown, Maryland-based company said the FDA review of its next-generation, 365-day, once-per-week calibration Eversense implantable continuous glucose monitor (CGM) is advancing as planned. It expects the progress to enable 510(k) clearance in the near future […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: ADA 2024, Senseonics

Senseonics posts Q1 sales beat, submits 365-day iCGM to FDA

May 13, 2024 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) shares ticked up after the market closed today on first-quarter results that came in ahead of the consensus sales forecast. Shares of SENS rose 8.1% to 41¢ apiece in post-market trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down slightly. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Senseonics

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 12
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS